Drug profile · INN
bulevirtide
HEPCLUDEX
bulevirtide (HEPCLUDEX) is a bile acid transporter inhibitor.
Drug details — bulevirtide
- Class
- Antiinfectives for systemic use (J05)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
bulevirtide (HEPCLUDEX) is a bile acid transporter inhibitor.
Key facts
Mechanism of action
Bile acid transporter inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.
Gilead's Hepcludex Secures FDA Approval: Implications for Pharma
Gilead Sciences' Hepcludex has received FDA approval for hepatitis D, marking a significant milestone after previous manufacturing setbacks. This article explores the implications for the pharmaceutical industry.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bulevirtide?
bulevirtide (HEPCLUDEX) is a bile acid transporter inhibitor.
What is the brand name for bulevirtide?
HEPCLUDEX is a marketed brand name for bulevirtide. Check FDA Drugs@FDA for the current US label holder and prescribing information.